<DOC>
	<DOC>NCT00303589</DOC>
	<brief_summary>This 3 arm study will compare the efficacy and safety of beta-lactam with that of 'standard care' in patients with complicated skin and skin structure infections requiring hospitalization. Patients will be randomized to receive 1)beta-lactam 750mg iv q8h 2)beta-lactam 1500mg iv q8h or 3)'standard care' [PRP (nafcillin or flucloxacillin) or vancomycin, plus aztreonam or ciprofloxacin]. The anticipated time on study treatment is &lt;3 months and the target sample size is 100-500 individuals.</brief_summary>
	<brief_title>A Study of Beta-Lactam in Hospitalized Patients With Skin and Skin Structure Infections</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Soft Tissue Infections</mesh_term>
	<mesh_term>beta-Lactams</mesh_term>
	<mesh_term>Lactams</mesh_term>
	<criteria>adult patients, &gt;=18 years of age; skin or skin structure infection requiring hospitalization; clinical diagnosis of a skin or skin structure infection caused by bacteria known or suspected to be susceptible to the randomized study treatment; material from site of infection is clinically purulent or seropurulent. presenting with sustained shock (SBP&lt;90mm Hg for &gt; 2 hours, despite adequate fluid resuscitation); known or suspected concomitant bacterial infection requiring antibiotic treatment; skin infection or chronic nonhealing ulcer of &gt; 2 weeks duration; patients in whom surgery is the primary treatment.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>